

VAXONO

**VACCINES: PRESENT AND FUTURE
IN ONCOLOGY**

Milan (Italy)

October 1st, 2024

NH COLLECTION MILANO CITYLIFE

Via Bartolomeo Colleoni,14

Organizing Secretariat



VAXONO

**VACCINES: PRESENT AND FUTURE
IN ONCOLOGY**

PRESIDENCY

Paolo A. Ascierto

*Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit,
National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy*

Bernard A. Fox

*Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer
Research Center in the Earle A. Chiles Research Institute at Providence Cancer Institute,
Portland, Oregon, US*

RATIONAL

*After decades of research and clinical trials, vaccines are beginning to impact patient
outcomes. While the future is bright, we still have a long way to go.*

*This event will be an international meeting for experts to share and discuss the latest findings
and future perspectives on cancer vaccines. The objectives of the conference are to:*

- *Present up-to-date data.*
- *Interpret clinical and scientific findings and predict potential impact.*
- *Recognize and characterize the hurdles that remain.*
- *Provide a vision for the future if hurdles are addressed*

*There will be panel discussions embedded in each session to address questions raised by
presentations, allow time to consider visions for the future, identify the hurdles that remain,
and summarize areas of consensus and/or disagreement.*

Program

09.30 am Introduction and objectives of the Meeting
Paolo A. Ascierto, Bernard A. Fox

SESSION 1

**The cancer immunopeptidome : neoantigens, TAAs,
and dark matter – alternative cancer neoantigens**

Chairpersons: Paolo A. Ascierto, Bernard A. Fox

09.40 am What gets into the HLA of cancer cells / basic science intro
Jonathan Yewdell

10.00 am Why are we just discovering dark matter now?
Bernard A. Fox

10.20 am Vaccines targeting cryptic peptides from Circ RNA provide
therapeutic effects
Erwei Song

10.40 am Discussion

01.10 am *Coffee break* **

SESSION 2

Vaccines with anti-PD-1

Chairpersons: Paolo A. Ascierto, Bernard A. Fox

- 11.30 am Neoantigen in Melanoma
Ryan Sullivan
- 11.50 am Personalized mRNA vaccines in pancreatic cancer
Pablo Guasp
- 12.10 am IDO/PD-L1 targeting peptide vaccine + anti-PD-1
Inge Marie Svane
- 12.30 am Discussion
- 01.00 pm *Lunch* **

SESSION 3

Are universal or histology specific cancer vaccines possible?

Chairpersons: Paolo A. Ascierto, Bernard A. Fox

- 02.00 pm Non-canonical antigens in pancreatic cancer:
clues for next-generation therapies
William Freed-Pastor
- 02.20 pm Identification of colorectal cancer antigens and evaluation of RNA
Vaccines in a Mouse Model
Pierre Thibault
- 02.40 pm Neoantigen Vaccines: Shared vs. Personalized Approaches
Nina Bhardwaj
- 03.00 pm Discussion
- 03.30 pm *Coffee break* **

SESSION 4

Beyond PD-1: combination immunotherapy with vaccines

Chairpersons: **Paolo A. Ascierto, Bernard A. Fox**

- 03.45pm VAX On T Cell Agonist
Lei Zheng
- 04.05pm Dark Matter Vaccine in Head & Neck Cancer
Rom Leidner
- 04.25pm HPV SLP with anti-PD-1
Kees Melief
- 04.45pm Actual landscape and perspectives on Immunotherapy
in Melanoma treatment
Paolo A. Ascierto
- 05.05pm Discussion
- 05.25pm Take home messages and conclusions
Paolo A. Ascierto, Bernard A. Fox

**Not included in the CME accredited

Faculty

PAOLO A. ASCIERTO, Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS “Fondazione G. Pascale”, Naples, Italy

NINA BHARDWAJ, Director of Immunotherapy; Medical Director of the Vaccine and Cell Therapy Laboratory; Ward-Coleman Chair in Cancer Research; Professor of Medicine (Hematology and Medical Oncology) and Urology, The Tisch Cancer Institute at Mount Sinai, New York, NY, US

BERNARD A. FOX, Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Institute, Portland, Oregon, US

WILLIAM FREED-PASTOR, Assistant Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School; Department of Medical Oncology, Division of Molecular and Cellular Oncology, Hale Center for Pancreatic Cancer Research, DFCI, Boston, Massachusetts, US; Associate Member, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, US

PABLO GUASP, Research Associate; Human Oncology and Pathogenesis Program; Memorial Sloan Kettering Cancer Center, New York, NY, US

ROM LEIDNER, Medical Director Head & Neck Cancer Program, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon, US

KEES MELIEF, Emeritus Professor at Leiden University Medical Center, Leiden, The Netherlands

ERWEI SONG, Professor of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

RYAN SULLIVAN, Associate Professor, Medicine, Hematology, Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, US

INGE MARIE SVANE, Professor in Clinical cancer immune therapy and director of the translational research centre, Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen, Denmark

PIERRE THIBAUT, Professor and CAPA director, Institute for Research in Immunology and Cancer, Montreal, Canada

JONATHAN YEWDELL, Senior Investigator, Cellular Biology & Viral Immunology, National Institutes of Health, NIAID/DIR, Bethesda, Maryland, US

LEI ZHENG, Professor of Oncology; Co-director of the Pancreatic Cancer Precision Medicine Center of Excellence Program at the Johns Hopkins School of Medicine, Baltimore, Maryland, US

CME - CONTINUING MEDICAL EDUCATION

ID CME 936-426648 Ed. 1

7 CME credits.

Formative Technical Professional Objective “Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease and gender medicine”.

80 participants (medical doctors, pharmacists, biologists, nurses, pediatric nurses).

In order to receive CME credits, participants must:

1. attend at least 90% of the accredited CME sessions (attendance check: required signat the beginning and at the end of works);
2. fill in the CME test (minimum 75% correct answers required);
3. fill in the evaluation form

CME certificate will be sent at the end of the validation procedure.

REGISTRATION

Registration is free of charge.

For registration, please visit: www.vivenko.net/vaxon/

For information, please send an e-mail to: eventi@vivenko.net

OFFICIAL LANGUAGE

The official language is English.

CME PROVIDER

Via Campania 5, 73100 Lecce
Via Cola di Rienzo 290, 00192 Roma
e-mail: formazione@istitutosantachiara.it



ISTITUTO
SANTA CHIARA

PROVIDER COD. IDENTIFICATIVO 936

ORGANIZING SECRETARIAT

Vivenko srl Società Benefit
Via E. De Amicis, 42 - 20123 Milano
eventi@vivenko.net
www.vivenko.net

